Sign In
Buy GLP
$48.46
-0.170 (-0.350%)
At Close: Jul 29, 2026
Novo Nordisk Just Took a Big Swing, Slashing Its GLP-1 Drug Prices. Will It Pay Off for the Healthcare Giant?
04:30am, Sunday, 23'rd Nov 2025
Novo Nordisk has lost ground in the weight-loss drug market to Eli Lilly and telehealth companies. The company's new CEO is being far more aggressive, which bodes well.
2 Major Stocks Want to Dominate the GLP-1 Market. Which One Looks Like the Leader Heading Into 2026?
06:13pm, Saturday, 22'nd Nov 2025
Eli Lilly is currently the leader in the field and still has strong momentum. Novo Nordisk has made some moves that it hopes will help it catch up.
Is GLP-1 the new AI? Drugmaker Eli Lilly briefly joined the $1 trillion market cap club.
10:40am, Friday, 21'st Nov 2025
Eli Lilly briefly crossed the $1 trillion market cap threshold, the first drug maker to ever reach that milestone.
Beyond GLP-1: Eli Lilly's Expanding Drug Portfolio Lifts Sales
08:06am, Thursday, 20'th Nov 2025
LLY???s newest approvals and pipeline deals add fresh momentum to revenue growth as the company expands beyond its GLP-1 blockbusters.
Focus: High-stakes Novo Nordisk Alzheimer's studies could yield answers on GLP-1 benefit
06:04am, Thursday, 20'th Nov 2025
Studies from Novo Nordisk due early next month will give the strongest indication yet of whether blockbuster GLP-1 drugs - a class being used by millions for diabetes and weight loss - can slow progre
Researchers move closer to matching patients with GLP-1 drug that works best for them
05:59pm, Wednesday, 19'th Nov 2025
U.S. researchers are beginning to identify clinical characteristics that distinguish “super responders” to GLP-1 weight-loss drugs like Wegovy and Zepbound from patients who lose only moderate amo
SureNano Announces Non-Binding Letter of Intent to Negotiate Proposed Transaction of GlucaPharm Inc. for GLP-1 Drug Development
04:30pm, Wednesday, 19'th Nov 2025
Vancouver, British Columbia--(Newsfile Corp. - November 19, 2025) - SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) (the "Company" or "SureNano") is pleased to announce it has entered into a non-bind
Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting
06:37pm, Monday, 17'th Nov 2025
Vanda's Tradipitant Study Success Positions it as Key Adjunct in $50B+ Global GLP-1 Agonist Market WASHINGTON , Nov. 17, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), a leadi
Novo Nordisk: Modeling A GLP-1 Giant In Retreat And Recovery
04:25pm, Monday, 17'th Nov 2025
Novo Nordisk faces intensifying GLP-1 competition, notably from Eli Lilly, prompting price cuts for Wegovy to expand market access and defend share. NVO's long-term upside relies on broadening semaglu
Wellgistics Health to Distribute Tollo Health GLP-1 Companion Muscle Loss Medical Food to Pharmacies & Physicians
09:00am, Friday, 14'th Nov 2025
Company to offer the first clinically validated dietary management of sarcopenia, now available for GLP-1 muscle loss, positioning Wellgistics to help 6,500+ independent pharmacy network (‘Pharmacy
Could GLP-1 Drugs Make ResMed's CPAP Machines Obsolete?
02:00pm, Wednesday, 12'th Nov 2025
GLP-1 drugs pose an existential threat to CPAP-makers. ResMed is currently experiencing temporary tailwinds before potential long-term headwinds.
GLP-1 prices are dropping: Who exactly will benefit?
10:25am, Tuesday, 11'th Nov 2025
CNBC's Bertha Coombs asks President Trump and his team at the White House's announcement on lower prices for Eli Lilly and Novo Nordisk's GLP-1 medications, if those new prices will extend to commerci
New Research from RGA: GLP-1s Expected to Reduce US Mortality by 3.5% Over the Next 20 Years
09:00am, Tuesday, 11'th Nov 2025
ST. LOUIS--(BUSINESS WIRE)--Reinsurance Group of America, Incorporated (NYSE: RGA), a leading global life and health reinsurer, published new in-depth research quantifying the mortality and morbidity
Who's Winning the Intense Battle to Rule the White-Hot GLP-1 Drug Market?
04:25am, Tuesday, 11'th Nov 2025
Eli Lilly's GLP-1 drug is now the world's best-selling drug. Novo Nordisk is struggling with declining market share.
Will Lower GLP-1 Prices Undermine Novo Nordisk's Near-Term Outlook?
11:31am, Monday, 10'th Nov 2025
NVO's new U.S. pricing deal for Ozempic and Wegovy expands access but adds uncertainty to its growth and profit outlook.
